Michael Seiden

Michael Seiden has led the clinical development of the methylation-based targeted sequencing technology underlying the Galleri MCED test, establishing that cfDNA methylation patterns are far more informative than mutation analysis alone for multi-cancer detection because methylation changes are tissue-specific and abundant across the genome. His work optimized the targeted methylation sequencing assay that interrogates over 100,000 methylation regions to achieve the balance of sensitivity and specificity required for population screening. He has guided the analytical validation framework ensuring reproducibility across clinical laboratories. His technological development has made large-scale MCED screening practically achievable.